0001610618false00016106182024-05-142024-05-14

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 14, 2024
  
Cidara Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
 
 
 
Delaware 001-36912 46-1537286
(State or Other Jurisdiction of
Incorporation or Organization)		 (Commission File Number) (I.R.S. Employer
Identification Number)
 
6310 Nancy Ridge Drive, Suite 101
San Diego, California 92121
(858) 752-6170
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, Par Value $0.0001 Per ShareCDTXThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(f) Bonus Determinations for Fiscal Year 2023
On May 14, 2024, the Board of Directors of Cidara Therapeutics, Inc. (the “Company”) completed its determination of the annual bonus amounts for the Company’s named executive officers earned pursuant to its annual performance-based cash bonus program for the fiscal year ending December 31, 2023. This information was not included in the Summary Compensation Table in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “2023 Form 10-K”), filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 22, 2024, because the amounts had not been determined at the time of filing the 2023 Form 10-K. In accordance with Item 5.02(f) of Form 8-K, the Company is providing a revised Summary Compensation Table and revised Pay Versus Performance Tables.
Summary Compensation Table
NAME AND PRINCIPAL POSITIONYEARSALARY
STOCK AWARDS (1)
OPTION AWARDS (2)
NON-EQUITY INCENTIVE PLAN COMPENSATION (3)
ALL OTHER COMPENSATION (4)
TOTAL
Jeffrey Stein, Ph.D.
President and
Chief Executive Officer		2023$593,800 $274,468 $388,276 $292,100 $9,900 $1,558,544 
Taylor Sandison, M.D., M.P.H.
Chief Medical Officer		2023$487,100 $90,900 $128,592 $167,600 $9,900 $884,092 
Shane Ward
Chief Operating Officer
Chief Legal Officer and
Corporate Secretary		2023$454,640 $127,934 $180,981 $156,400 $9,900 $929,855 
(1)    The amount reported in this column for 2023 represents the aggregate grant date fair value of restricted stock unit awards granted during 2023 under the Company’s 2015 Plan, computed in accordance with ASC Topic 718. The assumptions used in calculating the grant date fair value of these equity awards reported in this column are set forth in Note 8 to the Company’s audited consolidated financial statements included in its 2023 Form 10-K. This amount does not reflect the actual economic value that may be realized by Drs. Stein and Sandison and Mr. Ward.
(2)    In accordance with SEC rules, this column reflects the aggregate grant date fair value of the option awards granted during 2023 computed in accordance with ASC 718. Assumptions used in the calculation of these amounts are included in Note 8 to the Company’s audited consolidated financial statements included in its 2023 Form 10-K. This amount does not reflect the actual economic value that may be realized by Drs. Stein and Sandison and Mr. Ward.
(3)    Reflects amounts earned pursuant to the Company’s annual performance-based cash bonus program.
(4)    Represents Company 401(k) plan matching contributions to each named executive officer.
Required Tabular Disclosure of Pay Versus Performance
The amounts set forth below under the headings “Compensation Actually Paid to PEO” and “Average Compensation Actually Paid to Non-PEO NEOs” have been calculated in a manner consistent with Item 402(v) of Regulation S-K. Use of the term “compensation actually paid” is required by the SEC’s rules and as a result of the calculation methodology required by the SEC, such amounts differ from compensation actually received by the individuals and the compensation decisions described in the “Executive and Director Compensation” section above. The Company’s Chief Executive Officer is its principal executive officer and is referred to as PEO in the headers in the following tables.
Year
Summary Compensation Table Total for PEO (1)
Compensation Actually Paid to PEO (2)
Average Summary Compensation Table Total for Non-PEO NEOs (3)
Average Compensation Actually Paid to Non-PEO NEOs (4)
Value of Initial Fixed $100 Investment Based on Total Stockholder Return (“TSR”) (5)
Net Loss (thousands) (6)
(a)(b)(c)(d)(e)(f)(g)
2023$1,558,544 $1,601,757 $906,974 $907,897 $39.70 $(22,931)
(1)    The dollar amounts reported in column (b) are the amounts of total compensation reported for Dr. Stein for each corresponding year in the “Total” column of the Summary Compensation Table. Refer to “Executive and Director Compensation—Summary Compensation Table”.


(2)    The dollar amounts reported in column (c) represent the amount of “compensation actually paid” to Dr. Stein, as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual amount of compensation earned by or paid to Dr. Stein during the applicable year. In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to Dr. Stein’s total compensation for each year to determine the compensation actually paid:
YearReported Summary Compensation Table Total for PEO
Subtract: Reported Value of Equity Awards (a)
Add: Equity Award Adjustments (b)
Compensation Actually Paid to PEO
2023$1,558,544 $662,744 $705,957 $1,601,757 
(a)    The grant date fair value of equity awards represents the sum of the totals of the amounts reported in the “Stock Awards” and “Option Awards” columns in the Summary Compensation Table for the applicable year.
(b)    The equity award adjustments for each applicable year include the addition (or subtraction, as applicable) of the following: (i) the year-end fair value of any equity awards granted in the applicable year that are outstanding and unvested as of the end of the year; (ii) the amount of change as of the end of the applicable year (from the end of the prior fiscal year) in fair value of any awards granted in prior years that are outstanding and unvested as of the end of the applicable year; (iii) for awards that are granted and vest in same applicable year, the fair value as of the vesting date; (iv) for awards granted in prior years that vest in the applicable year, the amount equal to the change as of the vesting date (from the end of the prior fiscal year) in fair value; (v) for awards granted in prior years that are determined to fail to meet the applicable vesting conditions during the applicable year, a deduction for the amount equal to the fair value at the end of the prior fiscal year; and (vi) the dollar value of any dividends or other earnings paid on stock or option awards in the applicable year prior to the vesting date that are not otherwise reflected in the fair value of such award or included in any other component of total compensation for the applicable year. The amounts deducted or added in calculating the equity award adjustments are as follows:
YearAdd: Year End Fair Value of Outstanding and Unvested Equity Awards Granted in the YearAdd: Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior YearsAdd: Fair Value as of Vesting Date of Equity Awards Granted and Vested in the YearAdd: Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the YearSubtract: Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the YearAdd: Value of Dividends or other Earnings Paid on Stock or Option Awards not Otherwise Reflected in Fair Value or Total CompensationTotal Equity Award Adjustments
2023$438,878 $16,849 $88,719 $161,511 $— $— $705,957 
(3)    The dollar amounts reported in column (d) represent the average of the amounts reported for the Company’s named executive officers as a group (excluding the PEO) in the “Total” column of the Summary Compensation Table in each applicable year.
(4)    The dollar amounts reported in column (e) represent the average amount of “compensation actually paid” to the named executive officers as a group (excluding the PEO), as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual average amount of compensation earned by or paid to the named executive officers as a group (excluding the PEO) during the applicable year. In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to average total compensation for the named executive officers as a group (excluding the PEO) for each year to determine the compensation actually paid, using the same methodology described above in Note (2):
YearAverage Reported Summary Compensation Table Total for Non-PEO NEOsSubtract: Average Reported Value of Equity Awards
Add: Average Equity Award Adjustments (a)
Average Compensation Actually Paid to Non-PEO NEOs
2023$906,974 $264,204 $265,127 $907,897 
(a)    The amounts deducted or added in calculating the total average equity award adjustments are as follows:
YearAdd: Average Year End Fair Value of Outstanding and Unvested Equity Awards Granted in the YearAdd: Year over Year Average Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior YearsAdd: Average Fair Value as of Vesting Date of Equity Awards Granted and Vested in the YearAdd: Year over Year Average Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the YearSubtract: Average Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the YearAdd: Average Value of Dividends or other Earnings Paid on Stock or Option Awards not Otherwise Reflected in Fair Value or Total CompensationTotal Average Equity Award Adjustments
2023$174,959 $5,920 $35,368 $48,880 $— $— $265,127 
(5)    TSR is determined based on the value of an initial fixed investment of $100 on December 31, 2020. Cumulative TSR reported in column (f) is calculated by dividing the sum of the cumulative amount of dividends for the measurement


period, assuming dividend reinvestment, and the difference between the Company’s share price at the end and the beginning of the measurement period by the Company’s share price at the beginning of the measurement period. No dividends were paid on stock or option awards in 2023.
(6)    The dollar amount reported in column (g) represents the amount of net loss reflected in the Company’s consolidated audited financial statements included in its 2023 Form 10-K.



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 Cidara Therapeutics, Inc.
   
Date: May 20, 2024 /s/ Jeffrey Stein, Ph.D.
   Jeffrey Stein, Ph.D.
   President and Chief Executive Officer
(Principal Executive Officer)


v3.24.1.1.u2
Cover Page
May 14, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date May 14, 2024
Entity Registrant Name Cidara Therapeutics, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-36912
Entity Tax Identification Number 46-1537286
Entity Address, Address Line One 6310 Nancy Ridge Drive,
Entity Address, Address Line Two Suite 101
Entity Address, City or Town San Diego,
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code 858
Local Phone Number 752-6170
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, Par Value $0.0001 Per Share
Trading Symbol CDTX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001610618
Amendment Flag false
Cidara Therapeutics (NASDAQ:CDTX)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024 Click aqui para mais gráficos Cidara Therapeutics.
Cidara Therapeutics (NASDAQ:CDTX)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024 Click aqui para mais gráficos Cidara Therapeutics.